http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode ESC heart failure 8(6) Sokolski, Mateusz Rainer, Peter P. Wallner, Markus Chiodini, Alessandra Heiniger, Pascal S. Mikulicic, Fran Schwaiger, Judith Winnik, Stephan Cakmak, Huseyin A. Gaudenzi, Margherita Mapelli, Massimo Mattavelli, Irene Paul, Matthias Cabac-Pogorevici, Irina Bouleti, Claire Lilliu, Marzia Minoia, Chiara Dauw, Jeroen Costa, Jerome Celik, Ahmet Mawton, Nathan Montenegro, Carlos E.L. Matsue, Yaya Lončar, Goran Marchel, Michal Bechlioulis, Aris Michalis, Lampros Dorr, Marcus Prihadi, Edgard Schoenrath, Felix Messroghli, Daniel R. Mullens, Wilfried Lund, Lars H. Rosano, Giuseppe M.C. Ponikowski, Piotr Ruschitzka, Frank Flammer, Andreas J. Muster, Viktoria Ablasser, Klemens Sinagra, Gianfranco Stolfo, Davide Pouleur, Anne-Catherine Skaarup, Kristoffer G. Barge-Caballero, Eduardo Hojbjerg Lassen, Mats C. Biering-Sorensen, Tor Poku, Nana K. Meyer, Philippe D'Amario, Domenico Sokolska, Justyna M. Trenson, Sander Heart failure in COVID-19 application/pdf 2518506 bytes eng 2021 Key words: COVID-19, SARS-CoV2, heart failure, cardiovascular disease, risk factors info:eu-repo/semantics/article AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44–2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01–2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24–4.29], P < 0.001). CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality. https://unilib.phaidrabg.rs/o:2864 doi:10.1002/ehf2.13549 cobiss:125644809 ISSN: 1941-3289